HOME >> BIOLOGY >> NEWS
A tumour suppressor in mice and men

Prof. Reinhard Fässler, showed that the transcription factor is helped by a molecular "ticket".

Large numbers of ubiquitin molecules can be attached in sequence to proteins. A certain kind of binding marks this protein as "rubbish" which has to be removed. Another type of ubiquitin attachment to proteins functions as a kind of transport signal. It negotiates the transfer, for example, of proteins into the nucleus. The study shows that this is the case with Bcl-3. It only functions like this, however, when Cyld does not get in the way. This protein was first found in patients suffering from cylindromas. These are tumours that grow on the face, neck, and scalp. Cyld is a deubiquitinase - an enzyme that removes ubiquitin groups from other proteins. "We could show in our study that Cyld proteins can accumulate around the nucleus," says Fässler. "They can intercept Bcl-3 there and prevent it from being imported into the nucleus, by removing ubiquitin appendages." This is the first evidence ever of a specific mechanism that regulates and controls the Bcl-3 oncogene.

The team of researchers from Munich flawlessly reconstructed Cyld interaction with Bcl-3. They demonstrated every step in the process, from the recruiting of Cyld over to the nuclear membrane, to the ubiquitinisation of Bcl-3, and Cyld's reversal of this process. They also showed in detail that Bcl-3 collects without Cyld in the nucleus, and can cause cell proliferation with p50 and p52. All in all, it seems not unlikely that Cyld functions as a tumour suppressor in mice and in humans. In humans, there is evidence that a defective Cyld gene can have negative consequences, like the largely benign tumours of cylindromas. The researchers also found very little, or no, Cyld in the cells of other skin tumours. The situation is similar in some cases of liver, kidney, and uterine cancer. "Cyld is expressed in every cell in the body", Fässler says. "I believe personally that the deubiquitinase activit
'"/>

Contact: Eva-Maria Diehl
diehl@biochem.mpg.de
49-898-578-2824
Max-Planck-Gesellschaft
29-May-2006


Page: 1 2 3

Related biology news :

1. Research team develops cancer-curing T-lymphocyte-based therapy to eradicate malignant tumours
2. Sick Kids researchers confirm that cancer stem cells initiate and grow brain tumours
3. Multicenter study nets new lung tumor-suppressor gene
4. MicroRNAs can be tumor suppressors
5. MicroRNAs as tumor suppressors
6. Novel regulation of the common tumor suppressor PTEN
7. Tumor-suppressor gene is critical for placenta development
8. Novel regulatory mechanism identified for key tumor suppressor p53
9. A tumor suppressor that promotes cancer cell growth?
10. Structure determined for p53 tumor suppressor protein as bound to DNA for anti-cancer activity
11. Mutation in tumor suppressor gene causes pancreatic islet cells to reproduce

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: tumour suppressor mice and men

(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
(Date:4/27/2015)... 27, 2015  For about a century, a ... ability to utilize and catabolize glucose at a ... is called the ,Warburg phenomenon", that is an ... oxygen presence, leading to enhanced lactate generation. Even ... choose glucose fermentation. A variety of such abnormalities ...
(Date:4/27/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... year ended December 31, 2014. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... provide the outcome management and investors had hoped ... Therapeutics", said Andrew Rae , President & ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 ... patente para un nuevo receptor utilizando tecnología de descubrimiento ... no cubierta en el tratamiento de millones de pacientes ... anunciado hoy que ha recibido una patente en Europa ... el descubrimiento de Molecular Health de que EPHB4 es ...
(Date:4/27/2015)... Calif. (PRWEB) April 27, 2015 Dr. ... drug and chemical toxicity carries implications for advancing the ... April 28 at National University , the second-largest ... presentation by Dr. Hanzlik, a professor at the University ... metabolism and drug design, starts at 5 p.m. and ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
Cached News: